Metrnl/Meteorin-like/IL-41, a novel regulator of bone metabolism and disease activity in ankylosing spondylitis: based on multi-omics analysis

BackgroundAnkylosing spondylitis (AS) is an autoimmune disease characterized by bone destruction and abnormal remodeling. Metrnl, a secreted protein involved in inflammation and immune regulation, has recently been linked to bone growth. This study aimed to evaluate serum Metrnl levels in AS patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhuoqi Li, Tao Sun, Min Zhao, Liping Xia, Hui Shen
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1595181/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849712127218024448
author Zhuoqi Li
Zhuoqi Li
Tao Sun
Min Zhao
Liping Xia
Hui Shen
author_facet Zhuoqi Li
Zhuoqi Li
Tao Sun
Min Zhao
Liping Xia
Hui Shen
author_sort Zhuoqi Li
collection DOAJ
description BackgroundAnkylosing spondylitis (AS) is an autoimmune disease characterized by bone destruction and abnormal remodeling. Metrnl, a secreted protein involved in inflammation and immune regulation, has recently been linked to bone growth. This study aimed to evaluate serum Metrnl levels in AS patients and explore its bone regulatory mechanisms using cell models and multi-omics analyses.MethodsA total of 275 participants aged 16–60 years were included to measure serum Metrnl levels using Enzyme-Linked-Immunosorbent Assay (ELISA). Correlation and receiver operating characteristic (ROC) curve analyses assessed the diagnostic and predictive value of Metrnl. Mouse pre-osteoblastic MC3T3-E1 cells were treated with recombinant Metrnl (0/10/50 ng/mL) during 28-day osteogenic differentiation. RT-qPCR and alkaline phosphatase (ALP)/Alizarin Red S (ARS) staining was used to evaluate direct osteogenic differentiation effects. Transcriptomic and proteomic studies were conducted to further explore bone metabolism mechanisms. Finally, multi-omics integration analyses identified key pathways and targets.ResultsElevated serum Metrnl levels correlated directly with disease activity markers (CRP, ESR, IL-6) in AS-Active patients, but not in AS-Stable patients. ROC analysis validated Metrnl as a potential auxiliary diagnostic biomarker for high disease activity. In vitro, Metrnl suppressed ALP/OCN expression without altering overall osteogenic differentiation. Transcriptomic and proteomic analyses revealed Metrnl’s regulatory effects on osteogenic genes and proteins, emphasizing its role in bone and cartilage development. Bioinformatics highlighted Metrnl’s inhibition of endochondral ossification, delaying cartilage development and promoting osteoclast differentiation. Multi-omics integration identified Aspn and Sp7 as key targets in bone remodeling and resorption balance.ConclusionsMetrnl may serve as an additional diagnostic biomarker for AS and as an indicator for monitoring AS disease activity. Besides, Metrnl plays a critical role in regulating cartilage and bone metabolism and maintaining bone homeostasis, providing new insights for the future diagnosis and treatment of bone-related diseases.
format Article
id doaj-art-269b57c24bb545b28f0e7afa1627a8e1
institution DOAJ
issn 1664-3224
language English
publishDate 2025-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-269b57c24bb545b28f0e7afa1627a8e12025-08-20T03:14:23ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-07-011610.3389/fimmu.2025.15951811595181Metrnl/Meteorin-like/IL-41, a novel regulator of bone metabolism and disease activity in ankylosing spondylitis: based on multi-omics analysisZhuoqi Li0Zhuoqi Li1Tao Sun2Min Zhao3Liping Xia4Hui Shen5Department of Rheumatology and Immunology, The First Hospital of China Medical University, China Medical University, Shenyang, ChinaNational Clinical Research Center for Laboratory Medicine, Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, ChinaDepartment of Rheumatology and Immunology, The First Hospital of China Medical University, China Medical University, Shenyang, ChinaNational Clinical Research Center for Laboratory Medicine, Department of Laboratory Medicine, The First Hospital of China Medical University, Shenyang, ChinaDepartment of Rheumatology and Immunology, The First Hospital of China Medical University, China Medical University, Shenyang, ChinaDepartment of Rheumatology and Immunology, The First Hospital of China Medical University, China Medical University, Shenyang, ChinaBackgroundAnkylosing spondylitis (AS) is an autoimmune disease characterized by bone destruction and abnormal remodeling. Metrnl, a secreted protein involved in inflammation and immune regulation, has recently been linked to bone growth. This study aimed to evaluate serum Metrnl levels in AS patients and explore its bone regulatory mechanisms using cell models and multi-omics analyses.MethodsA total of 275 participants aged 16–60 years were included to measure serum Metrnl levels using Enzyme-Linked-Immunosorbent Assay (ELISA). Correlation and receiver operating characteristic (ROC) curve analyses assessed the diagnostic and predictive value of Metrnl. Mouse pre-osteoblastic MC3T3-E1 cells were treated with recombinant Metrnl (0/10/50 ng/mL) during 28-day osteogenic differentiation. RT-qPCR and alkaline phosphatase (ALP)/Alizarin Red S (ARS) staining was used to evaluate direct osteogenic differentiation effects. Transcriptomic and proteomic studies were conducted to further explore bone metabolism mechanisms. Finally, multi-omics integration analyses identified key pathways and targets.ResultsElevated serum Metrnl levels correlated directly with disease activity markers (CRP, ESR, IL-6) in AS-Active patients, but not in AS-Stable patients. ROC analysis validated Metrnl as a potential auxiliary diagnostic biomarker for high disease activity. In vitro, Metrnl suppressed ALP/OCN expression without altering overall osteogenic differentiation. Transcriptomic and proteomic analyses revealed Metrnl’s regulatory effects on osteogenic genes and proteins, emphasizing its role in bone and cartilage development. Bioinformatics highlighted Metrnl’s inhibition of endochondral ossification, delaying cartilage development and promoting osteoclast differentiation. Multi-omics integration identified Aspn and Sp7 as key targets in bone remodeling and resorption balance.ConclusionsMetrnl may serve as an additional diagnostic biomarker for AS and as an indicator for monitoring AS disease activity. Besides, Metrnl plays a critical role in regulating cartilage and bone metabolism and maintaining bone homeostasis, providing new insights for the future diagnosis and treatment of bone-related diseases.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1595181/fullMetrnlautoimmune diseasebiomarkermulti-omicsbone metabolism
spellingShingle Zhuoqi Li
Zhuoqi Li
Tao Sun
Min Zhao
Liping Xia
Hui Shen
Metrnl/Meteorin-like/IL-41, a novel regulator of bone metabolism and disease activity in ankylosing spondylitis: based on multi-omics analysis
Frontiers in Immunology
Metrnl
autoimmune disease
biomarker
multi-omics
bone metabolism
title Metrnl/Meteorin-like/IL-41, a novel regulator of bone metabolism and disease activity in ankylosing spondylitis: based on multi-omics analysis
title_full Metrnl/Meteorin-like/IL-41, a novel regulator of bone metabolism and disease activity in ankylosing spondylitis: based on multi-omics analysis
title_fullStr Metrnl/Meteorin-like/IL-41, a novel regulator of bone metabolism and disease activity in ankylosing spondylitis: based on multi-omics analysis
title_full_unstemmed Metrnl/Meteorin-like/IL-41, a novel regulator of bone metabolism and disease activity in ankylosing spondylitis: based on multi-omics analysis
title_short Metrnl/Meteorin-like/IL-41, a novel regulator of bone metabolism and disease activity in ankylosing spondylitis: based on multi-omics analysis
title_sort metrnl meteorin like il 41 a novel regulator of bone metabolism and disease activity in ankylosing spondylitis based on multi omics analysis
topic Metrnl
autoimmune disease
biomarker
multi-omics
bone metabolism
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1595181/full
work_keys_str_mv AT zhuoqili metrnlmeteorinlikeil41anovelregulatorofbonemetabolismanddiseaseactivityinankylosingspondylitisbasedonmultiomicsanalysis
AT zhuoqili metrnlmeteorinlikeil41anovelregulatorofbonemetabolismanddiseaseactivityinankylosingspondylitisbasedonmultiomicsanalysis
AT taosun metrnlmeteorinlikeil41anovelregulatorofbonemetabolismanddiseaseactivityinankylosingspondylitisbasedonmultiomicsanalysis
AT minzhao metrnlmeteorinlikeil41anovelregulatorofbonemetabolismanddiseaseactivityinankylosingspondylitisbasedonmultiomicsanalysis
AT lipingxia metrnlmeteorinlikeil41anovelregulatorofbonemetabolismanddiseaseactivityinankylosingspondylitisbasedonmultiomicsanalysis
AT huishen metrnlmeteorinlikeil41anovelregulatorofbonemetabolismanddiseaseactivityinankylosingspondylitisbasedonmultiomicsanalysis